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inter-laboratory variance for all MDSC subsets, especially 
for the granulocytic subsets. In particular, the use of a dead-
cell marker altered significantly the reported percentage of 
granulocytic MDSCs, confirming that these cells are espe-
cially sensitive to cryopreservation and/or thawing. Impor-
tantly, the gating strategy was heterogeneous and associ-
ated with high inter-center variance. Overall, our results 
document the high variability in MDSC phenotyping in 
the multicenter setting if no harmonization/standardization 
measures are applied. Although the observed variability 
depended on a number of identified parameters, the main 
parameter associated with variation was the gating strat-
egy. Based on these findings, we propose further efforts 
to harmonize marker combinations and gating parameters 
to identify strategies for a robust enumeration of MDSC 
subsets.
Keywords Myeloid-derived suppressor cells · 
Phenotyping · Proficiency panel · Flow cytometry
Abstract There is an increasing interest for monitoring 
circulating myeloid-derived suppressor cells (MDSCs) in 
cancer patients, but there are also divergences in their phe-
notypic definition. To overcome this obstacle, the Cancer 
Immunoguiding Program under the umbrella of the Asso-
ciation of Cancer Immunotherapy is coordinating a pro-
ficiency panel program that aims at harmonizing MDSC 
phenotyping. After a consultation period, a two-stage 
approach was designed to harmonize MDSC phenotype. 
In the first step, an international consortium of 23 labora-
tories immunophenotyped 10 putative MDSC subsets on 
pretested, peripheral blood mononuclear cells of healthy 
donors to assess the level of concordance and define robust 
marker combinations for the identification of circulat-
ing MDSCs. At this stage, no mandatory requirements to 
standardize reagents or protocols were introduced. Data 
analysis revealed a small intra-laboratory, but very high 
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Abbreviations
CIMT  Association for Cancer Immunotherapy
CIP  CIMT Immunoguiding Program
DCM  Dead-cell marker
G-MDSC  Granulocytic MDSC
i-MDSC  Immature MDSC
M-MDSC  Monocytic MDSC
n% MDSC  Normalized MDSC frequencies
Introduction
Myeloid-derived suppressor cells (MDSCs) are a hetero-
geneous group of myeloid cells at different stages of dif-
ferentiation that are often expanded in cancer patients and 
capable to suppress immune responses [1]. In recent years, 
recognition of the clinical relevance of MDSCs has stead-
ily increased. MDSC levels correlate negatively with prog-
nosis and overall survival in cancer patients, and the accu-
mulation of this population promotes tumor progression 
and is linked to tumor stage and worse prognosis of cancer 
patients [2–5].
MDSCs were originally described in mice, on the basis 
of the co-expression of CD11b and Gr-1. However, sub-
sequent studies elucidated that CD11b+/Gr-1+ cells are 
not a homogeneous cell population, but rather a hetero-
geneous group of myeloid cells, endowed with different 
suppressive ability. At present, it is well known that there 
are at least two main subsets of MDSCs present in tumor-
bearing mice, the monocytic (M-MDSC) and the granulo-
cytic (G-MDSC) ones and that these cell populations can 
be properly identified by using a set of accessory mark-
ers. In particular, the differential expression of Ly6C and 
Ly6G, the two isoforms of Gr-1, allows the identification 
of G-MDSC as CD11b+/Gr-1high/Ly6C−/Ly6Ghigh and 
M-MDSC as CD11b+/Gr-1int/Ly6Chigh/Ly6G− [6].
The phenotyping of human MDSCs is complicated by 
the fact that Gr-1 is not expressed on human leukocytes. 
Thus, multiple human MDSC subsets with different pheno-
types have been documented in several types of tumors in 
the last 20 years (reviewed in [7]). All reported phenotypes 
are defined on the basis of a combination of myeloid mark-
ers and suffer from the lack of a specific marker. The initial 
assumption that MDSCs are solely constituted of immature 
myeloid cells [8–10] is now challenged by reports describ-
ing MDSCs with morphology and phenotype consistent 
with those of cells with more differentiated features. At pre-
sent, it appears that all MDSC phenotypes can be allocated 
to one of the at least three main subsets, of which each 
contains more than one cell population. M-MDSCs share 
the morphology of monocytes and are characterized by the 
expression of CD14 and lack of CD15 [11, 12]; G-MDSCs 
contain a cell population resembling granulocytes and are 
phenotypically characterized by CD15 and CD66b expres-
sion and the absence of CD14 [12–16]; immature MDSCs 
(i-MDSC) are cells with immaturity characteristics, defined 
essentially as lineage negative cells [3, 17].
Although there is an increasing relevance of MDSCs for 
tumor immunology, there is lack of a uniformly used and 
broadly accepted classification of human MDSCs (in terms 
of both subsets types and identification markers). This 
motivated the design of a proficiency panel by the CIMT 
(Association for Cancer Immunotherapy) Immunoguid-
ing Program (CIP) (http://www.cimt.eu/workgroups/cip/) 
to assess the heterogeneity in current human MDSC phe-
notyping approaches and harmonize them across different 
laboratories. The first step of the proficiency panel, which 
is the focus of this communication, did not include a func-
tional assay, since the suppressive activity of most of these 
subsets was already reported [7]; hence, this study was 
mainly designed to assess intra-laboratory and inter-labora-
tory variance and to define a robust marker combination for 
the phenotypical identification of circulating MDSCs. The 
parameters associated with high variance identified from 
this first phase will be harmonized in the second step with 
the aim to decrease the variability of MDSC quantification.
Materials and methods
Healthy donors
After given written informed consent, leukapheresis was 
performed for 23 healthy individuals. Peripheral blood 
mononuclear cells (PBMCs) were centrally prepared by 
Ficoll gradient and cryopreserved as described previously 
[4]. The healthy donors were screened by flow cytometry 
for the presence of the 10 putative MDSC subsets by the 
organizing committee, and three representative donors 
with the most significant expansion of these subsets were 
selected for the first phase of the proficiency panel.
Proficiency panel
Two vials of each donor were shipped to the participant 
laboratories in dry ice and stored in liquid nitrogen upon 
arrival. The participating laboratories were asked to per-
form the immunophenotyping of 10 putative subsets of 
MDSCs on the cryopreserved samples from the three 
selected healthy donors (HBC-480, HBC-514, L29-3). 
Experiment guidelines to indicate the mandatory param-
eters to be fulfilled and with exemplary staining cock-
tails, protocol and gating strategy (Fig. 1) were provided 
to the participants. The proposed staining cocktails con-
tain 7 markers commonly used for MDSC recognition (as 
deduced from two webinars held on MDSCs by CIP) plus a 
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dead-cell marker (DCM): HLA-DR, CD14, CD15, CD11b, 
CD33, lineage cocktail (defined as CD3/14/19/56) and 
CD124. This marker combination allows the identification 
of 10 putative MDSC subsets: MDSC1 CD14+/CD124+ 
[12]), MDSC2 CD15+/CD124+ [12], MDSC3 Lin−/HLA-
DR−/CD33+ [10], MDSC4 CD14+/HLA-DRlow/− [11], 
MDSC5 CD15+/CD14−/CD11b+ [15], MDSC6 CD15+/
FSClow/SSChigh [13], MDSC7 CD15−/CD14+/CD33high/
HLA-DRlow [18], MDSC8 CD15+/CD33high, MDSC9 
CD14−/CD15−/CD33high and MDSC10 Lin−/HLA-DRlow/
CD11b+ [19]. Participants were asked to perform the stain-
ing twice, in two separate days, in order to calculate intra-
laboratory variance. For each donor in each of the two 
experimental runs, participants were asked to determine 
cell viability after thawing, test and report the number of 
total cells, singlets, monocytes and lymphocytes plus 10 
putative MDSC phenotypes using one 8-color panel and/or 
three 4-color antibody flow cytometry panels.
In addition, guidelines indicated to use at least one mil-
lion PBMCs per test, not to perform a resting period after 
thawing the cells and not to fix the stained cells.
Participants were asked to analyze the flow data using 
their own gating strategy and to report it in single layouts; 
moreover, they were asked to determine the absolute num-
ber of the requested cell populations with or without the 
presence of a DCM.
Central data analysis
Results from the 23 participating laboratories were cen-
trally collected and analyzed. Absolute numbers of the 10 
putative MDSC subsets were normalized to the count of 
lymphocytes + monocytes. Variance was calculated as fol-
lows: %CV = (standard deviation/mean)*100. Comparison 
between %CV or normalized frequencies of myeloid sub-
sets identified by different groups was performed using the 
Wilcoxon signed-rank test. Significance level was set for 
P < 0.05.
Results
To start this project, we conducted a survey by sending 
out a questionnaire to groups that the organizers identified 
as having published at least one paper on human MDSCs. 
We explored their interest in participating to a harmoniza-
tion process for the phenotyping of human MDSCs. Results 
of 89 analyzed questionnaires were discussed at the CIMT 
Annual Meeting 2012 and in two webinars hold in Sep-
tember 2012 with more than 50 participants. Most research 
groups expressed strong interest to join this activity and, in 
particular, to reach an agreement for the markers required to 
phenotype MDSCs. From the initial survey, it appeared that 
overall 32 markers were used to define MDSCs, but only a 
core set of 7 markers was commonly used by all groups.
On the basis of these results, a consensus could be 
reached among the webinar participants to define the fol-
lowing 7 markers describing 10 different putative subsets 
of MDSCs for further testing: MDSC1 CD14+/CD124+ 
[12], MDSC2 CD15+/CD124+ [12], MDSC3 Lin−/HLA-
DR−/CD33+ [10, 20], MDSC4 CD14+/HLA-DRlow/− [11], 
MDSC5 CD15+/CD14−/CD11b+ [15], MDSC6 CD15+/
FSClow/SSChigh [13], MDSC7 CD15−/CD14+/CD33high/
HLA-DRlow/− [18], MDSC8 CD15+/CD33high, MDSC9 
CD14−/CD15−/CD33high and MDSC10 Lin−/HLA-
DRlow/−/CD11b+ [19]. Lineage (Lin) was defined by the 
cocktail of anti-CD3/14/19/56 antibodies.
For ethical and practical reasons, it was not feasible to 
obtain leukaphereses from cancer patients, and therefore, 
PBMCs of healthy donors were used for this harmonization 
panel. Participants were asked to phenotype the samples for 
the 10 predefined putative MDSC subsets. A total of 23 lab-
oratories (15 European and 8 from the USA) participated 
to the proficiency panel and reported their results to the 
organizing committee.
Participants were asked to stain the PBMC with antibod-
ies against HLA-DR, CD14, CD15, CD11b, CD33, line-
age cocktail (defined as specified above) and CD124 plus 
a dead-cell marker (DCM). The participating laboratories 
chose gating strategy, antibody clones and fluorochromes, 
protocol for staining, negative controls and the inclusion of 
additional markers. An exemplary, but optional, gating strat-
egy was provided in the guidelines (Fig. 1). We mandated 
that centers would use either one 8-color antibody panel or 
three 4-color antibody panels to combine the 8 proposed 
markers and to perform two experimental runs for each 
donor on different days. As readout, participants reported 
the number of total events, lymphocytes, monocytes and 
MDSC subsets in either the presence or absence of DCM.
For each MDSC subset and each donor, we calculated 
the intra-assay and inter-assay variance (%CV) of each 
reported MDSC subset frequency.
Intra-laboratory variance was as expected for multicolor 
phenotyping assays within a lower range (range 20–45 %, 
Fig. 2a). However, data analysis revealed large inter-lab-
oratory variance among the 10 MDSC subsets analyzed, 
ranging from 50 to 300 %, with the highest variance among 
the granulocytic subsets compared to the immature and 
monocytic subsets (Fig. 2b). When analyzing the influence 
of data normalization, we found that normalizing MDSC 
frequencies (n% MDSC) to either lymphocytes or lympho-
cytes + monocytes generally reduced variance (Fig. 2c). 
Exemplary data of individual laboratories for three subsets 
are shown in Fig. 3 (panels a, b and c), and the descrip-
tive statistics of the results is reported in Supplementary 
Table 1.
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Fig. 1  Exemplary gating strategy included in the panel’s guideline. 
The figure shows the gating strategy proposed in the guidelines and 
made of three sequential steps, allowing the identification of the 10 
putative MDSC subsets. Step 1 consists in doublets exclusion fol-
lowed by dead-cell exclusion. Step 2 allows the identification of three 
MDSC subsets (MDSC1-2-8), and from a consecutive gate, the other 
seven defined MDSC populations are identified in step 3
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In view of the large spread of the data, we set out to 
identify the potential sources of variability in the phenotyp-
ing of the 10 MDSC subsets. Accordingly, we analyzed the 
n% MDSC and the %CV obtained from the analysis per-
formed with or without DCM. Results indicate that the use 
of DCM decreases the  n% MDSC of G-MDSC (MDSC2, 
5, 6 and 8), M-MDSC MDSC1 and i-MDSC (MDSC3 and 
10) but not of monocytic subsets MDSC4 and 7 (Fig. 4a). 
The explanation for these results probably lies on the frag-
ile nature of granulocytic cells, which are more prone to 
cell death during the cryopreservation and/or thawing pro-
cedure than either monocytic subsets or lymphocytes [6, 
21]. The use of a dead-cell marker did not significantly 
affect the variance of results obtained from two tests per-
formed by the same laboratory (intra-laboratory; Fig. 2a), 
while it increased the inter-laboratory variance of results 
(Fig. 2b; P < 0.0001, Wilcoxon matched-pair test).
Other parameters, such as antibody clones and the use 
of 8-color versus 4-color panels, were difficult to analyze, 
because the large number of subgroups identified for each 
variable led to numbers too small for statistical approaches. 
However, results suggest that the choice of negative con-
trols, CD124 clone and composition of the lineage cocktail 
were associated with high inter-laboratory variation (data 
not shown).
It is well known that one of the sources of inter-labo-
ratory variability arises from manual gating analysis of 
flow cytometry data [22–24], and, indeed, we observed 
a large variability in the gating strategy developed by the 
participating groups. For example, some participants put 
the gate for CD124+ cells only on highly fluorescent cells, 
while others gated positive cells including also dimly fluo-
rescent cells; as a consequence, total %CV for MDSC1 is 
twofold higher than the %CV calculated within each of 
the two groups that use a similar gating strategy to identify 
CD124+ cells (data not shown). Also the gating of CD33 
positive cells was differently performed including CD33 
low and/or high cells, thereby increasing the variance. To 
dissect the influence of gating analysis on the result vari-
ance, we grouped the laboratories that followed the gating 
example provided in our guidelines (Fig. 1) for the iden-
tification of the 10 MDSC subsets. We observed that for 
those participant results following a homogeneous gating 
approach, the %CV was reduced (P = 0.0012, Wilcoxon 
matched-pair test) for most MDSC subsets, especially for 
G-MDSCs (Fig. 4b).
Discussion
Circulating levels of MDSCs have been correlated with 
tumor burden and overall survival in different types of 
cancer, and some studies demonstrated their prognostic 
role for the outcomes of different chemotherapeutic regi-
mens (reviewed in [7]). Therefore, it is a promising bio-
marker now also for response to immunotherapy. However, 
Fig. 2  Analysis of the impact of a dead-cell marker on MDSC quan-
tification. Black bars indicate average %CV from analyses performed 
without exclusion of dead cells, while white bars refer to analyses 
considering only live cells (n = 18 evaluable laboratories report-
ing data for the 8-color panel). Intra-laboratory variance is shown in 
panel a, while panel b reports inter-laboratory variance. c Average 
%CV (n = 14 evaluable laboratories reporting data for the 8-color 
panel) of the frequencies of the ten MDSC subsets without normali-
zation (black bar) and normalized on the number of singlets (yellow 
bar), lymphocytes (blue bar) and lymphocytes + monocytes (red 
bar)
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the validation of the predictive significance of MDSCs in 
multicenter studies is complicated by the phenotypic com-
plexity of human MDSCs, thereby creating a challenge 
in finding a consensus on the minimal requirements for 
MDSC monitoring. To address this challenge, we organ-
ized the first proficiency panel to harmonize human MDSC 
phenotyping.
The task was challenging because of the large number 
of participants, the complexity of the staining panel and 
the number of subsets to be identified. Under these circum-
stances, it is not surprising that the quantification of the 
10 requested MDSC subsets was characterized by a high 
inter-laboratory variance, increasing from monocytic to 
immature and granulocytic subsets. The number and the 
international origin of the participating laboratories indi-
cate that the high inter-laboratory variance observed in the 
panel could be similar as in independent studies on human 
MDSC published. In contrast, the intra-laboratory vari-
ance was in general not high, indicating that the participat-
ing laboratories were experienced in the field of multicolor 
flow cytometry.
The choice of reagents and the gating strategy were 
critical parameters that impacted on the quantification of 
MDSC. The participating laboratories had been allowed 
Fig. 3  Values of a repre-
sentative subsets of monocytic 
(MDSC4 – panel a), granulo-
cytic (MDSC5 – panel b) and 
immature (MDSC10 – panel c) 
MDSCs are shown as examples. 
Frequencies were normal-
ized on the count of lympho-
cytes + monocytes for each lab-
oratory performing either one 
8-color panel or three 4-color 
panels for MDSC identification; 
the two paired histograms refer 
to the two independent experi-
mental runs performed by each 
laboratory (black bars = first 
run, gray bars = second run). 
Missing values, not reported by 
single laboratories, were labeled 
with “m”
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to decide on staining reagents. As a result, a consider-
able number of different antibodies were used to iden-
tify MDSC subsets using an 8-color staining panel. We 
observed that the clone of anti-CD124 antibody and the 
composition of the lineage cocktail significantly influ-
enced the quantification of CD124+ MDSCs and imma-
ture MDSCs, respectively. The issue of the heterogene-
ity of reagents was also present in previous proficiency 
panels, in which a partial standardization of reagents had 
been suggested [25], especially for culturing of PBMCs 
intended to be used for functional T cell assays [23, 26, 
27]. The MDSC proficiency panel introduced the use of 
a DCM, and, as expected, we observed that the percent-
ages of several MDSC subsets, and in particular of gran-
ulocytic ones, were significantly reduced by dead-cell 
exclusion. Hence, these results raise the question whether 
dead MDSCs should also be evaluated in frozen samples 
to account for their presence in fresh samples, or in con-
trast, whether inclusion of dead cells would alter MDSC 
quantification due to unspecific binding of antibodies to 
other cell types.
The gating strategies used for identification of MDSC 
subsets had a significant influence on the variance of 
results. Inter-laboratory performance improved signifi-
cantly when analysis was limited to only those laborato-
ries, which applied a homogenous gating strategy similar to 
that proposed in the panel’s guidelines. This was not unex-
pected since most proficiency panels based on flow cytome-
try similarly recommend harmonization of the gating strat-
egies across laboratories. In a multimer-based proficiency 
panel, results were audited in order to exclude wet labora-
tories which regularly used a wrong gating procedure [24, 
25]. However, since identification of MDSC subsets derives 
from a complex combination of markers, we believe that a 
more adequate approach would be to train the participating 
laboratories to perform a properly gating pipeline through 
an in silico panel, as done in ICS proficiency panels [23, 
28]. Hence, we are currently setting up an in silico panel to 
measure the influence of manual gating analysis on the var-
iance of the results. In this study, participants will be asked 
to re-analyze their own data, as well as those of a supple-
mentary reference dataset, following guided instructions 
for sequential gating. The output will guide us to design the 
second step of the proficiency panel in which harmoniza-
tion should be achieved following a wider set of mandatory 
requests, dealing not only with gating procedure but also 
with other parameters such as the use of a DCM, a unique 
lineage cocktail, and fluorescence-minus-one controls for 
dimly fluorescent antigens.
Conclusion
Overall, this interim report emphasizes the lack of a robust 
definition for human MDSC subsets and highlights the 
importance of finding an agreement on the harmonized 
staining and analysis strategy and of translating our find-
ings in general guidelines for immune phenotyping of these 
cells. We demonstrated that it is feasible to conduct a pro-
ficiency panel including a large number of participants and 
identifying a high number of myeloid subsets using 8-color 
flow cytometry. In this first step, we provided individual 
feedback of performance for each laboratory and we iden-
tified a number of parameters that must be harmonized in 
the second step, hence establishing the foundation for the 
development of a robust assay for MDSC phenotyping.
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